IRIS UniCatt

Biolato, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.852
NA - Nord America 1.607
AS - Asia 865
SA - Sud America 168
AF - Africa 16
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 4
Totale 4.517
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.590
DE - Germania 534
SE - Svezia 379
SG - Singapore 333
IT - Italia 300
CN - Cina 291
BR - Brasile 157
IE - Irlanda 122
UA - Ucraina 107
FR - Francia 99
ID - Indonesia 77
GB - Regno Unito 76
FI - Finlandia 64
RU - Federazione Russa 64
IN - India 50
BE - Belgio 26
KR - Corea 25
TR - Turchia 23
HK - Hong Kong 14
PL - Polonia 13
CA - Canada 11
NL - Olanda 10
AT - Austria 9
BD - Bangladesh 8
CZ - Repubblica Ceca 7
IR - Iran 7
JP - Giappone 7
GR - Grecia 6
LT - Lituania 6
RO - Romania 6
VN - Vietnam 6
CH - Svizzera 5
CI - Costa d'Avorio 5
DK - Danimarca 5
ES - Italia 5
PE - Perù 5
AR - Argentina 4
AU - Australia 4
EU - Europa 4
PK - Pakistan 4
ZA - Sudafrica 4
AE - Emirati Arabi Uniti 3
EG - Egitto 2
HU - Ungheria 2
IL - Israele 2
KG - Kirghizistan 2
KH - Cambogia 2
LK - Sri Lanka 2
PA - Panama 2
PH - Filippine 2
RE - Reunion 2
TW - Taiwan 2
AL - Albania 1
BZ - Belize 1
CG - Congo 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EC - Ecuador 1
EE - Estonia 1
IS - Islanda 1
KZ - Kazakistan 1
LV - Lettonia 1
MA - Marocco 1
MN - Mongolia 1
MY - Malesia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PT - Portogallo 1
RS - Serbia 1
TH - Thailandia 1
UY - Uruguay 1
Totale 4.517
Salva come PNG Salva come JPEG
Città #
Chandler 322
Singapore 223
Ashburn 155
Dublin 122
Jakarta 74
New York 72
Rome 71
Milan 67
Jacksonville 60
San Mateo 51
Nanjing 49
Wilmington 46
Cattolica 41
Chicago 38
Helsinki 38
Boston 37
Los Angeles 36
Dearborn 35
Moscow 33
Marseille 31
Princeton 28
Munich 27
The Dalles 27
Brussels 26
Hefei 26
Seoul 25
Ann Arbor 22
Frankfurt am Main 22
Beijing 21
Nürnberg 19
Woodbridge 19
Redwood City 17
Saint Petersburg 17
Augusta 15
Izmir 15
Nanchang 15
Bremen 14
Falls Church 13
London 13
São Paulo 13
Nuremberg 12
Seattle 12
Changsha 11
Hong Kong 11
Tianjin 11
Boardman 10
Hebei 10
Kraków 10
Norwalk 10
Shenyang 10
Fairfield 9
Santa Clara 9
Falkenstein 8
Houston 8
Kunming 8
Lauterbourg 8
Lawrence 8
Atlanta 7
Düsseldorf 7
Guangzhou 7
North Bergen 7
Turku 7
Amsterdam 6
Brno 6
Jiaxing 6
Lancaster 6
Leawood 6
Portland 6
Portsmouth 6
San Diego 6
Washington 6
Abidjan 5
Athens 5
Fremont 5
Lima 5
Palermo 5
Rio de Janeiro 5
Toronto 5
Zhengzhou 5
Edinburgh 4
Jinan 4
Mountain View 4
Ottawa 4
Pune 4
Shanghai 4
University Park 4
Andover 3
Bexley 3
Casalecchio di Reno 3
Curitiba 3
Dallas 3
Dhaka 3
Genoa 3
Hangzhou 3
Hanoi 3
Hounslow 3
Istanbul 3
Kish 3
Lappeenranta 3
Manchester 3
Totale 2.359
Salva come PNG Salva come JPEG
Nome #
A phase II study of sunitinib in advanced hepatocellular carcinoma 214
Abdominal angina due to recurrence of cancer of the papilla of vater: a case report. 189
Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis 169
Vanishing-recurrent benign liver lesions 128
Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: serum sodium predicts survival 126
[The treatment of hepatocellular carcinoma: an update] 120
Quando e perché fermarsi nelle terapie: l’opinione del clinico e del bioeticista sui casi di HCC avanzato. 112
Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis 109
Liver transplantation in patients with alcoholic liver disease: A retrospective study 108
Intestinal permeability after Mediterranean diet and low-fat diet in non-alcoholic fatty liver disease 106
Severe giant cell arteritis associated with essential thrombocythaemia. 98
Comment on "the role of endoscopic ultrasound in the evaluation of chronic mesenteric ischaemia" 98
TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib 97
Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease 96
Clinical characteristics of metabolic associated fatty liver disease (MAFLD) in subjects with myotonic dystrophy type 1 (DM1) 91
A giant calcified hepatic mass 85
The diagnostic performance of PIVKA-II in metabolic and viral hepatocellular carcinoma: A pilot study 83
Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma 82
Mediterranean diet and the prevention of non-alcoholic fatty liver disease: Results from a case-control study 82
A peculiar cause of small-bowel intussusception and iron deficiency anaemia 81
Enhanced liver fibrosis test as a reliable tool for assessing fibrosis in nonalcoholic fatty liver disease in a clinical setting 80
A novel ABCB11 variant in compound heterozygosity: BRIC2 or PFIC2? 79
Drug-induced liver injury 2017: the diagnosis is not easy but always to keep in mind 75
Ventricular thrombosis during sorafenib therapy for advanced hepatocellular carcinoma 73
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 71
Acute HEV hepatitis: clinical and laboratory diagnosis 66
Post-liver transplant intrahepatic cholestasis: etiology, clinical presentation, therapy 65
Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients 63
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program 59
Personalized Therapy in a Multidisciplinary Team Improves Survival in Patient with HCC: The Hepatocatt Experience 58
MetaLiverCat: the NAFLD/NASH multidisciplinary board at Fondazione Policlinico Gemelli IRCCS 58
Liver transplantation for drug-induced acute liver failure 58
Fatty liver and drugs: the two sides of the same coin 56
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review 56
Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review 54
Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach 54
Acute hepatitis caused by a natural lipid-lowering product: when "alternative" medicine is no "alternative" at all 52
A peculiar cause of small-bowel intussusception and iron deficiency anaemia 48
Proposal of a new evidence based definition of Early Allograft Failure to identify patients who needs early retransplant and call for a prospective external validation study 47
PREVALENCE OF ADVANCED LIVER FIBROSIS AMONG PRIMARY CARE PATIENTS WITH NAFLD. RESULTS FROM GENERAL PRACTITIONER DATABASE NAFLD (GPS-NAFLD) STUDY 47
Acute liver failure in Still’s disease relapse during pregnancy: case report and discussion of a possible trigger role of DILI 47
Prognostic ability of BCLC-B subclassification in patients with hepatocellular carcinoma undergoing transarterial chemoembolization 46
Clinical impact of comorbidities in an Italian NAFLD cohort 44
FREQUENCY AND REASONS FOR NON-LISTING IN REFERRED ADULT PATIENTS FOR LIVER TRANSPLANTATION 43
ORGANIZATIONAL AND ECONOMIC ISSUES RELATED TO THE INTRODUCTION OF BOCEPREVIR IN THE TREATMENT OF PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C IN ITALY 42
Letter to the Editor: Suboptimal performance of CAR-OLT score to predict 1-year risk of cardiovascular events after liver transplantation 41
Correction to: Acute liver failure in Still’s disease relapse during pregnancy: case report and discussion of a possible trigger role of DILI (BMC Gastroenterology, (2021), 21, 1, (317), 10.1186/s12876-021-01878-3) 40
Correlation of the transaminases alteration with the clinical severity of patients with COVID-19: A meta-analysis of the first global outbreak 39
Liver stiffness in the early post-liver transplant phase as a marker of acute allograft rejection 39
Starvation hepatitis and refeeding-induced hepatitis: mechanism, diagnosis, and treatment 38
ELF TEST IS A RELIABLE NON INVASIVE TEST FOR FIBROSIS IN NAFLD SUBJECTS 37
A single course of lusutrombopag for multiple invasive procedures in cirrhosis-associated thrombocytopenia: A case series 37
SERUM SODIUM IS A PREDICTOR OF SURVIVAL FOR "INTERMEDIATE HCC" TREATED WITH TRANSARTERIAL CHEMIOEMBOLIZATION (TACE) 35
Branched chain amino acids in hepatic encephalopathy and sarcopenia in liver cirrhosis: Evidence and uncertainties 35
A PROPOSAL MODEL FOR THE NON-INVASIVE ASSESSMENT OF HISTOLOGICAL INFLAMMATION IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) 35
Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins? 34
FREQUENCY OF AND REASONS BEHIND NON-LISTING IN ADULT PATIENTS REFERRED FOR LIVER TRANSPLANTATION 33
Therapeutic Approach to Post-Transplant Recurrence of Hepatocellular Carcinoma: Certainties and Open Issues 33
COMMON CLINICAL COMORBIDITIES IN AN ITALIAN NAFLD COHORT 33
Multimorbidity and polypharmacotherapy in Italian primary care patients with NAFLD: General Practitioner databaSe NAFLD (GPS-NAFLD) Study 33
Two elective invasive procedures after a single avatrombopag treatment in a patient with liver cirrhosis and severe thrombocytopenia 32
Fib-4 score is able to predict intra-hospital mortality in 4 different SARS-COV2 waves 31
Steatohepatitis and type 2 diabetes mellitus are influenced by genetic susceptibility to increased intestinal permeability in patients with non-alcoholic fatty liver disease 30
Frequency of and reasons behind non-listing in adult patients referred for liver transplantation: Results from a retrospective study 30
Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis 29
Minimum platelet count threshold before invasive procedures in cirrhosis: Evolution of the guidelines 28
HEPATOMA ARTERIAL-EMBOLISATION PROGNOSTIC SCORE PREDICTS PROGRESSION IN HEPATOCELLULAR CARCINOMA TREATED BY RADIOFREQUENCY ABLATION PLUS TRANSARTERIAL CHEMOEMBOLIZATION 27
Liver functional reserve and survival after sunitinib therapy in cirrhotic patients with advanced hepatocellular carcinoma 24
FIBROSIS PROGRESSION DURING SUNITINIB THERAPY IN CIRRHOTIC PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA 22
THE 15 AND 30 MINUTES SAMPLING OF 13C-BREATH TESTING ARE ABLE TO PREDICT SEVERE HEPATIC FIBROSIS AND SEVERITY OF LIVER DISEASE 21
HEPARANASE IN NASH: IS IT AN USEFUL MARKER OF FIBROGENESIS? 21
Severe Cholestatic Hepatitis due to Temozolomide: An Adverse Drug Effect to Keep in Mind. Case Report and Review of Literature 19
Corrigendum to "Acute hepatitis caused by a natural lipid-lowering product: When "alternative" medicine is no "alternative" at all" [J Hepatol 50 (2009) 1273-1277] (DOI:10.1016/j.jhep.2009.02.021) 14
Abdominal angina 11
Totale 4.596
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.495
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.495
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202023 0 0 0 0 0 0 0 0 0 0 0 23
2020/2021245 4 25 10 35 38 10 25 9 33 13 36 7
2021/2022406 14 23 9 49 36 16 15 69 14 17 65 79
2022/20231.067 132 110 55 144 92 156 63 94 102 33 69 17
2023/2024705 48 170 26 46 33 109 45 33 13 39 47 96
2024/20251.164 30 29 124 55 107 53 41 61 201 130 309 24
Totale 4.596